Study #2024-0229
A study of the ApricityCare program for early detection and management of treatment-related adverse events in patients with metastatic cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Description
To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with metastatic cancer using ApricityCare. Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Cancer
Study phase:
Not applicable
Physician name:
Bilal Siddiqui
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-844-829-9300
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.